Lymphoma developing in a patient with long-term antitumor necrosis factor therapy

Lymphoma developing in a patient with long-term antitumor necrosis factor therapy

Bibliographic Details
Main Authors:	Giovana Serrão Fensterseifer, André Vicente Esteves de Carvalho, Ana Letícia Boff, Joel Schwartz
Format:	Article
Language:	English
Published:	Mattioli1885 2022-07-01
Series:	Dermatology Practical & Conceptual
Subjects:	lymphoma antiTNF adalimumab psoriasis
Online Access:	http://dpcj.org/index.php/dpc/article/view/2041

Similar Items

Hepatitis B reactivation and current clinical impact Reactivación de la hepatitis B y su impacto clínico actual
by: B. Álvarez Suárez, et al.
Published: (2010-09-01)

Diffuse large B-cell lymphoma that develops after adalimumab using adalimumab in a patient with psoriasis
by: Esra Yıldırım Bay, et al.
Published: (2021-06-01)

Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice
by: Maria Esposito, et al.
Published: (2019-07-01)

Adalimumab
by: Nilgun Atakan
Published: (2022-04-01)

Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report
by: Edyta Lelonek, et al.
Published: (2015-09-01)

Biological therapy in treatment of uveitis. Contemporary trends
by: A.V. Zborovskaia, et al.
Published: (2017-10-01)

Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study
by: Federica Ricceri, et al.
Published: (2022-05-01)

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)

Connections between rheumatology and oncology – discussions based on a case report
by: Laura Groseanu, et al.
Published: (2019-12-01)

Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review
by: Vidhi V. Shah, et al.
Published: (2018-08-01)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
by: Cristiano Pagnini, et al.
Published: (2021-09-01)

Unilateral Verrucous Psoriasis Successfully Treated With Adalimumab
by: Artur Antônio Duarte, et al.
Published: (2024-01-01)

Adalimumab in Treating Refractory Livedoid Vasculopathy
by: Xiao-Wen Huang, et al.
Published: (2022-04-01)

A Budget impact analysis of adalimumab biosimilar: the Italian context
by: Roberto Ravasio, et al.
Published: (2019-05-01)

Adalimumab-induced edema of the extremities in a psoriatic patient: a case report
by: Xiuqiu LIN, et al.
Published: (2023-08-01)

Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic
by: Elizabeth Adenubiova, et al.
Published: (2018-08-01)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
by: Cristina Membrive-Jiménez, et al.
Published: (2023-05-01)

Correlation of anti-TNF-a biological therapy with periodontal conditions and osteonecrosis in autoimmune patients: A systematic review
by: Rana Majdi Abunemer, et al.
Published: (2023-11-01)

Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab
by: Chen J, et al.
Published: (2022-11-01)

The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study
by: Dalia Shaaban, et al.
Published: (2018-01-01)

Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study
by: Aurore Dupont, et al.
Published: (2023-03-01)

Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima–Media Thickness Reduction
by: Manuel Sánchez-Díaz, et al.
Published: (2023-02-01)

A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
by: Thomas, T
Published: (2023)

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study
by: Ivan Guerra, et al.
Published: (2023-01-01)

Levels of antibodies to adalimumab in children with juvenile idiopathic arthritis at different stages of treatment
by: T.V. Marushko, et al.
Published: (2023-03-01)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023-04-01)

Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report
by: Fan D, et al.
Published: (2024-03-01)

Transition from secukinumab to adalimumab in COVID‐19‐induced psoriasis flare‐up treatment: A case report
by: Yuting Chen, et al.
Published: (2023-10-01)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
by: Elena Yurievna Loginova, et al.
Published: (2010-06-01)

Lithium-Associated Generalized Ostraceous Psoriasis Treated with Adalimumab: A Case Report
by: Yang Y, et al.
Published: (2023-04-01)

A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan
by: Chika Ohata, et al.
Published: (2019-01-01)

Multiple COVID reinfections in a vaccinated psoriatic patient receiving adalimumab
by: Omid Zargari, et al.
Published: (2022-11-01)

Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma
by: Caterina Lanna, et al.
Published: (2022-01-01)

Folliculitis decalvans managed with adalimumab: A case report
by: Adel Alsantali, et al.
Published: (2023-12-01)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023-07-01)

Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review
by: Yaxin Du, et al.
Published: (2022-08-01)

Shaping the Future of Behçet’s Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies
by: Biao Li, et al.
Published: (2023-07-01)

Case report: Cutaneous pseudolymphoma caused by a Leishmania infantum infection in a patient treated with anti-TNF antibody for plaque psoriasis
by: Sarah Scholl, et al.
Published: (2022-12-01)

Demyelinating Disease Following Anti-TNFa Treatment (Adalimumab) in Patients with psoriasis: A Case Report (PP-13)
by: Mohammadreza Malek Zadeh
Published: (2023-01-01)

Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis
by: Teppei Hagino, et al.
Published: (2023-01-01)